ArticleSAGE open medicine2025
Clinical significance of parathyroid hormone in mineral and glucose metabolism disorders among patients with primary aldosteronism.
Article in SAGE open medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the differences in mineral and glucose metabolic disorders among patients with primary aldosteronism, nonfunctional adrenal tumors, and controls. Methods: A retrospective analysis was conducted on clinical data from 578 patients, including those with primary aldosteronism, nonfunctional adrenal tumors, and control subjects, at our hospital between January 2013 and December 2023. Biochemical indices including parathyroid hormone, serum potassium, serum calcium, urine potassium, urine calcium, plasma renin, plasma aldosterone, glycosylated hemoglobin, insulin resistance index, and pancreatic beta cell function index were compared among the three groups. Results: Compared with the nonfunctional adrenal tumors and control groups, primary aldosteronism patients exhibited significantly higher levels of parathyroid hormone, urinary potassium, and aldosterone ( Conclusion: Primary aldosteronism is often characterized by elevated parathyroid hormone levels, which can exert direct adverse effects on mineral and glucose metabolism. Elevated parathyroid hormone levels serve as a valuable indicator in the screening of primary aldosteronism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.